newdwh2021/s3/data/crm/settings/CRM_MSJ_Patient__c.txt
shimoda.m@nds-tyo.co.jp 5a71bf972f MSJ_Patient__cの対応
2024-02-27 13:41:00 +09:00

14 lines
2.3 KiB
Plaintext

CRM
,
utf-8
"
CRLF
1
52
Id,OwnerId,IsDeleted,Name,CreatedDate,CreatedById,LastModifiedDate,LastModifiedById,SystemModstamp,MayEdit,IsLocked,MSJ_Account_Name__c,MSJ_CRC_Group__c,MSJ_Casus_or_Transfer_Point__c,MSJ_Entry_Date__c,MSJ_IST_Name__c,MSJ_Indication__c,MSJ_Line__c,MSJ_MR_Comments__c,MSJ_MUID__c,MSJ_Medical_Regimen__c,MSJ_Month__c,MSJ_Report_Comments__c,MSJ_Start_Date_Of_Administration__c,MSJ_Year__c,Mobile_ID_vod__c,MSJ_CRC_RAS_KRAS__c,MSJ_End_Date_Of_Administration__c,MSJ_End_Date_of_Stop_Administration__c,MSJ_HN_Hospitalized_Type__c,MSJ_Start_Date_of_Stop_Administration__c,MSJ_Patient_Status__c,MSJ_Patient_TA__c,MSJ_Child_Account_Name__c,MSJ_Child_Account__c,MSJ_Parent_Account_Name__c,MSJ_Parent_Child_Name__c,MSJ_Age__c,MSJ_Comments__c,MSJ_Effectiveness_evaluation_date__c,MSJ_Gender__c,MSJ_Informed_consent__c,MSJ_Metastases_location__c,MSJ_PS__c,MSJ_Scheduled_date_of_informed_consent__c,MSJ_Scheduled_start_date_administration__c,MSJ_CDX_type__c,MSJ_First_line_chemotherapy_efficacy__c,MSJ_Num_cycles_of_1st_line_chemotherapy__c,MSJ_Primary_site_location__c,MSJ_Regimen_of_first_line_chemotherapy__c,MSJ_Starting_dose__c
Id,OwnerId,IsDeleted,Name,CreatedDate,CreatedById,LastModifiedDate,LastModifiedById,SystemModstamp,MayEdit,IsLocked,MSJ_Account_Name__c,MSJ_CRC_Group__c,MSJ_Casus_or_Transfer_Point__c,MSJ_Entry_Date__c,MSJ_IST_Name__c,MSJ_Indication__c,MSJ_Line__c,MSJ_MR_Comments__c,MSJ_MUID__c,MSJ_Medical_Regimen__c,MSJ_Month__c,MSJ_Report_Comments__c,MSJ_Start_Date_Of_Administration__c,MSJ_Year__c,Mobile_ID_vod__c,MSJ_CRC_RAS_KRAS__c,MSJ_End_Date_Of_Administration__c,MSJ_End_Date_of_Stop_Administration__c,MSJ_HN_Hospitalized_Type__c,MSJ_Start_Date_of_Stop_Administration__c,MSJ_Patient_Status__c,MSJ_Patient_TA__c,MSJ_Child_Account_Name__c,MSJ_Child_Account__c,MSJ_Parent_Account_Name__c,MSJ_Parent_Child_Name__c,MSJ_Age__c,MSJ_Comments__c,MSJ_Effectiveness_evaluation_date__c,MSJ_Gender__c,MSJ_Informed_consent__c,MSJ_Metastases_location__c,MSJ_PS__c,MSJ_Scheduled_date_of_informed_consent__c,MSJ_Scheduled_start_date_administration__c,MSJ_CDX_type__c,MSJ_First_line_chemotherapy_efficacy__c,MSJ_Num_cycles_of_1st_line_chemotherapy__c,MSJ_Primary_site_location__c,MSJ_Regimen_of_first_line_chemotherapy__c,MSJ_Starting_dose__c
src02c.crm_MSJ_Patient__c
org02.crm_MSJ_Patient__c
CRM_MSJ_Patient__c_ex.sql